Sequencing by Synthesis to Contribute Significantly to miRNA Sequencing and Assay Market Worth US$ 1.4 Bn by 2032 - Persistence Market Research Report, 2023

Market Study on miRNA Sequencing: employment of newer approaches to extract the sequencing of miRNA to propel the market growth


New York, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The global miRNA Sequencing and Assay Market was valued at US$ 227.7 Mn in 2021 and is expected to reach US$ 1.4 Bn by 2032, finds Persistence Market Research in a recent market survey. As per the findings of the report, it is projected that revenue through Sequencing by Synthesis will expand with over 30% share throughout the analysis period.

The market is predicted to rise due to factors such as an increase in the frequency of infectious and communicable illnesses, technological advancements, and the employment of newer approaches to extract the sequencing of miRNA.

The growing interest in miRNA biomarker identification might enhance the miRNA sequencing and testing business. Furthermore, market growth is due to factors such as an increase in the frequency of neurological illnesses and a rising demand for personalized treatments.

Request for sample copy of report: https://www.persistencemarketresearch.com/samples/33228

Competitive Analysis
Some of the key companies operating in the miRNA Sequencing and Assay Market are Thermo Fisher Scientific, Illumina, QIAGEN, PerkinElmer, Abcam plc, New England Biolabs, Takara Bio Inc., Lexogen GmbH, Norgen Biotek Corp, Maravai LifeSciences, HTG Molecular Diagnostics, Meridian Bioscience, Inc., and System Biosciences, LLC.

Some of the recent developments in the miRNA Sequencing and Assay Market are:

  • In January 2022, research on Genome-Scale Study and Absolute Quantification of Circulating MicroRNA Biomarkers Using a MicroRNA Next-Generation-Sequencing Discovery Assay (miND) was conducted. For chronic and acute disorders as well as drug-induced harm, circulating levels of stem-cell microRNAs can be employed as diagnostic, disease severity, and prognostic indicators. As a result, the use of multivariate statistics to combine various microRNAs into marker signatures appears to be very potent in terms of tissues and disorder microRNA shed into the plasma.

  • In June 2020, the novel TraPR Small RNA Isolation Kit was announced by Lexogen, delivering the next sequencing firm. TraPR also known as Trans-Kingdom, Rapid, Affordable Purification of RISCs is a technology that allows for the cost-effective, accurate, and highly repeatable extraction of functional short RNAs (sRNAs) without the use of gels.

Know the methodology of report: https://www.persistencemarketresearch.com/methodology/33228

During the Covid-19 outbreak, the researchers found that SARS-CoV-2 RNA sequences interacted with human MicroRNAs for developing a vaccine. MicroRNAs (miRNA) are a new and significant component of the virus-host cell interaction. Although it has been hypothesized that host miRNAs have an influence on SARS-CoV-2 infection. By crossing two luciferase-based reporter plasmids containing virus target sequences or their reversed sequences into the lungs A549 cell line, their contact with virus sequences was experimentally confirmed. The reporter plasmids reduced luciferase activity in five of the eight possible binding sites after transfection, indicating that they are sensitive to endogenously produced miRNAs.

Get full access of report: https://www.persistencemarketresearch.com/checkout/33228

More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the miRNA Sequencing And Assay Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals extensive growth in miRNA Sequencing And Assay Market by Component (Product, Service), by Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection, Nanopore Seq., Sanger Seq. and Single Molecule Real-time Seq.), by Workflow (Library Preparation, Sequencing, and Data Analysis & Storage), by Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia and Other Applications) across five regions (North America, Asia Pacific, Europe, Middle East & Africa and Latin America).

Persistence Market Research’s Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations.

Other Trending Reports:

About Persistence Market Research:

Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

Contact

Rajendra Singh

Persistence Market Research

U.S. Sales Office:

305 Broadway, 7th Floor

New York City, NY 10007

+1-646-568-7751

United States

USA - Canada Toll-Free: 800-961-0353

Email: sales@persistencemarketresearch.com